FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912232420> ?p ?o ?g. }

• W2912232420 endingPage "1933" @default.
• W2912232420 startingPage "1923" @default.
• W2912232420 abstract "The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were randomized to four induction schedules for two cycles: STANDARD (idarubicin, cytarabine, etoposide); and azacitidine given prior (PRIOR), concurrently (CONCURRENT), or after (AFTER) therapy with idarubicin and etoposide. Consolidation therapy consisted of allogeneic hematopoietic-cell transplantation or three courses of high-dose cytarabine followed by 2-year maintenance therapy with azacitidine in the azacitidine-arms. AML with CBFB-MYH11, RUNX1-RUNX1T1, mutated NPM1, and FLT3-ITD were excluded and accrued to genotype-specific trials. The primary end point was response to induction therapy. The statistical design was based on an optimal two-stage design applied for each arm separately. During the first stage, 104 patients (median age 62.6, range 18-82 years) were randomized; the study arms PRIOR and CONCURRENT were terminated early due to inefficacy. After randomization of 268 patients, all azacitidine-containing arms showed inferior response rates compared to STANDARD. Event-free and overall survival were significantly inferior in the azacitidine-containing arms compared to the standard arm (p < 0.001 and p = 0.03, respectively). The data from this trial do not support the substitution of cytarabine by azacitidine in intensive induction therapy." @default.
• W2912232420 created "2019-02-21" @default.
• W2912232420 creator A5005056245 @default.
• W2912232420 creator A5006360930 @default.
• W2912232420 creator A5013231760 @default.
• W2912232420 creator A5013435653 @default.
• W2912232420 creator A5017172335 @default.
• W2912232420 creator A5020375942 @default.
• W2912232420 creator A5022178280 @default.
• W2912232420 creator A5026255080 @default.
• W2912232420 creator A5029448872 @default.
• W2912232420 creator A5029575769 @default.
• W2912232420 creator A5032138074 @default.
• W2912232420 creator A5040663053 @default.
• W2912232420 creator A5041544709 @default.
• W2912232420 creator A5048499083 @default.
• W2912232420 creator A5051240594 @default.
• W2912232420 creator A5053578678 @default.
• W2912232420 creator A5053949970 @default.
• W2912232420 creator A5053983155 @default.
• W2912232420 creator A5054636757 @default.
• W2912232420 creator A5055422099 @default.
• W2912232420 creator A5055477573 @default.
• W2912232420 creator A5058195823 @default.
• W2912232420 creator A5061331572 @default.
• W2912232420 creator A5069866186 @default.
• W2912232420 creator A5071708178 @default.
• W2912232420 creator A5073388713 @default.
• W2912232420 creator A5075459915 @default.
• W2912232420 creator A5081614049 @default.
• W2912232420 creator A5081804029 @default.
• W2912232420 creator A5084493873 @default.
• W2912232420 creator A5089395073 @default.
• W2912232420 date "2019-02-06" @default.
• W2912232420 modified "2023-10-15" @default.
• W2912232420 title "Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine" @default.
• W2912232420 cites W1558398160 @default.
• W2912232420 cites W1600365609 @default.
• W2912232420 cites W1904660196 @default.
• W2912232420 cites W1971211622 @default.
• W2912232420 cites W1986705681 @default.
• W2912232420 cites W1990814650 @default.
• W2912232420 cites W2025979353 @default.
• W2912232420 cites W2029409133 @default.
• W2912232420 cites W2041356430 @default.
• W2912232420 cites W2043216151 @default.
• W2912232420 cites W2106084333 @default.
• W2912232420 cites W2107398329 @default.
• W2912232420 cites W2116858301 @default.
• W2912232420 cites W2125482846 @default.
• W2912232420 cites W2137013563 @default.
• W2912232420 cites W2152496375 @default.
• W2912232420 cites W2164912656 @default.
• W2912232420 cites W2237124828 @default.
• W2912232420 cites W2278956317 @default.
• W2912232420 cites W2346974061 @default.
• W2912232420 cites W2412183643 @default.
• W2912232420 cites W2419140434 @default.
• W2912232420 cites W2474389367 @default.
• W2912232420 cites W2549790759 @default.
• W2912232420 cites W2559537906 @default.
• W2912232420 cites W2591153485 @default.
• W2912232420 cites W2606226563 @default.
• W2912232420 cites W2617245268 @default.
• W2912232420 cites W2623089849 @default.
• W2912232420 cites W2715749014 @default.
• W2912232420 cites W2766330759 @default.
• W2912232420 cites W2802281739 @default.
• W2912232420 cites W2892949113 @default.
• W2912232420 cites W2904378474 @default.
• W2912232420 cites W2912749909 @default.
• W2912232420 cites W2994749938 @default.
• W2912232420 cites W3175417087 @default.
• W2912232420 cites W4231346141 @default.
• W2912232420 doi "https://doi.org/10.1038/s41375-019-0395-y" @default.
• W2912232420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6756041" @default.
• W2912232420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30728457" @default.
• W2912232420 hasPublicationYear "2019" @default.
• W2912232420 type Work @default.
• W2912232420 sameAs 2912232420 @default.
• W2912232420 citedByCount "7" @default.
• W2912232420 countsByYear W29122324202019 @default.
• W2912232420 countsByYear W29122324202020 @default.
• W2912232420 countsByYear W29122324202021 @default.
• W2912232420 countsByYear W29122324202022 @default.
• W2912232420 crossrefType "journal-article" @default.
• W2912232420 hasAuthorship W2912232420A5005056245 @default.
• W2912232420 hasAuthorship W2912232420A5006360930 @default.
• W2912232420 hasAuthorship W2912232420A5013231760 @default.
• W2912232420 hasAuthorship W2912232420A5013435653 @default.
• W2912232420 hasAuthorship W2912232420A5017172335 @default.
• W2912232420 hasAuthorship W2912232420A5020375942 @default.
• W2912232420 hasAuthorship W2912232420A5022178280 @default.
• W2912232420 hasAuthorship W2912232420A5026255080 @default.
• W2912232420 hasAuthorship W2912232420A5029448872 @default.
• W2912232420 hasAuthorship W2912232420A5029575769 @default.
• W2912232420 hasAuthorship W2912232420A5032138074 @default.
• W2912232420 hasAuthorship W2912232420A5040663053 @default.

• next